drugset / Trial / NCT06774313
A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants
RandomizedSequentialQuadruple-blindBasic science
Summary
This study is designed to assess the pharmacokinetic properties, safety, tolerability, and immunogenicity of ABBV-142 and determine whether predicted efficacious exposures can be safely achieved in humans.
Timeline
- Start
- 2025-01-22
- Primary completion
- 2026-04-08
- Completion
- 2026-04-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABBV-142 | Unknown | — | Intravenous |
Indications
No indication recorded.